Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Sep 19;110(10):3267–3274. doi: 10.1111/cas.14178

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Comparison of lipid metabolite levels in multiple myeloma patients according to the response to bortezomib and low‐dose dexamethasone therapy. Six representative metabolites associated with the response to bortezomib and low‐dose dexamethasone therapy are shown. A, Phosphatidylcholine (PC)(18:0/20:3). B, Ether‐type phosphatidylethanolamine (ePE)(18:2e/18:2). C, ePE(16:0p/20:4). D, ePE(18:0p/20:4). E, Sphingomyelin (SM)(39:1). F, Cholesterol ester (ChE)(18:3). Graphs show the medians and interquartile ranges. Statistical significance was assessed using the Jonckheere‐Terpstra trend test. CR, complete response; IS, internal standard; MR, minor response; PD, progressive disease; PR, partial response; SD, stable disease; VGPR, very good partial response